Literature DB >> 26935171

Clinical manifestations and growth of patients with urea cycle disorders in Japan.

Kimitoshi Nakamura1, Jun Kido1, Shirou Matsumoto1, Hiroshi Mitsubuchi1, Fumio Endo1.   

Abstract

We have previously examined the clinical manifestations, treatments and prognosis of 177 patients with urea cycle disorders (UCDs) from January 1999 to March 2009 in Japan. In this study, we investigated the incidence of clinical manifestations in different peak blood ammonia level at onset in UCD patients, and examined the growth of OTCD (ornithine transcarbamylase deficiency) patients. The UCD patients who had a high peak blood ammonia level at onset showed significantly high incidence of convulsion and abnormal head computed tomography or magnetic resonance imaging. The patients also showed significantly high incidence of hemodialysis and liver transplantation. Choice of therapeutic agents for long-term treatment is not different between peak blood ammonia levels at the onset, except for the use of special amino-acid formulas. Growth retardation is not affected by high peak blood ammonia level at onset; however, 32% of male and 52% of female OTCD patients over 1 year old were plotted under the 10th percentile, and showed growth failure. The final height of the male and female OTCD patients were 166.2±5.5 and 150.3±7.2 cm, respectively. Although the prognosis of UCDs was improved significantly, it is considered that there are still many difficulties in the UCD patient's life.

Entities:  

Mesh:

Year:  2016        PMID: 26935171     DOI: 10.1038/jhg.2016.17

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  18 in total

1.  Long-term outcome and intervention of urea cycle disorders in Japan.

Authors:  Jun Kido; Kimitoshi Nakamura; Hiroshi Mitsubuchi; Toshihiro Ohura; Masaki Takayanagi; Masafumi Matsuo; Makoto Yoshino; Yosuke Shigematsu; Tohru Yorifuji; Mureo Kasahara; Reiko Horikawa; Fumio Endo
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

2.  Long-term treatment of girls with ornithine transcarbamylase deficiency.

Authors:  N E Maestri; S W Brusilow; D B Clissold; S S Bassett
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion.

Authors:  S W Brusilow
Journal:  Pediatr Res       Date:  1991-02       Impact factor: 3.756

4.  The nutritional management of urea cycle disorders.

Authors:  J V Leonard
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

5.  Dialysis in neonates with inborn errors of metabolism.

Authors:  F Schaefer; E Straube; J Oh; O Mehls; E Mayatepek
Journal:  Nephrol Dial Transplant       Date:  1999-04       Impact factor: 5.992

6.  Coexistence of a graft with the preserved native liver in auxiliary partial orthotopic liver transplantation from a living donor for ornithine transcarbamylase deficiency.

Authors:  S Uemoto; S Yabe; Y Inomata; H Nishizawa; K Asonuma; H Egawa; T Kiuchi; H Okajima; Y Yamaoka; H Yamabe; A Inui; T Fujisawa; K Tanaka
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

Review 7.  Alternative pathway therapy for urea cycle disorders.

Authors:  F Feillet; J V Leonard
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

8.  Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan.

Authors:  T Uchino; F Endo; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

Review 9.  Diagnosis and treatment of urea cycle disorder in Japan.

Authors:  Kimitoshi Nakamura; Jun Kido; Hiroshi Mitsubuchi; Fumio Endo
Journal:  Pediatr Int       Date:  2014-08       Impact factor: 1.524

10.  New pathways of nitrogen excretion in inborn errors of urea synthesis.

Authors:  S W Brusilow; D L Valle; M Batshaw
Journal:  Lancet       Date:  1979-09-01       Impact factor: 79.321

View more
  1 in total

1.  Long-term effects of medical management on growth and weight in individuals with urea cycle disorders.

Authors:  Roland Posset; Sven F Garbade; Florian Gleich; Andrea L Gropman; Pascale de Lonlay; Georg F Hoffmann; Angeles Garcia-Cazorla; Sandesh C S Nagamani; Matthias R Baumgartner; Andreas Schulze; Dries Dobbelaere; Marc Yudkoff; Stefan Kölker; Matthias Zielonka
Journal:  Sci Rep       Date:  2020-07-20       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.